Executive at Pfizer (NYSE: PFE) granted 259,844 stock appreciation rights

Rhea-AI Filing Summary

BOSHOFF CHRISTOFFEL reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. reported that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights on March 3, 2026. These derivative awards carry no purchase price and are part of his equity-based compensation.

The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, aligning the executive’s potential reward with long-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOSHOFF CHRISTOFFEL

Role President, R&D

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	259,844	$0.00	--

Holdings After Transaction: Stock Appreciation Rights — 259,844 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOSHOFF CHRISTOFFEL

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		259,844		03/03/2031(1)	03/03/2031(1)	Common Stock	259,844	$0.0000	259,844	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Christoffel Boshoff	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) disclose for Christoffel Boshoff?

Pfizer disclosed that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights. These awards are a form of equity-based compensation and will be settled in Pfizer common stock after meeting specified vesting conditions over time.

How many stock appreciation rights were granted in this Pfizer (PFE) Form 4?

Christoffel Boshoff was granted 259,844 stock appreciation rights. This entire amount was reported as directly owned following the transaction, reflecting a single equity award designed to link his compensation more closely to Pfizer’s long-term stock performance.

When will the granted Pfizer (PFE) stock appreciation rights be settled?

The stock appreciation rights granted to Christoffel Boshoff will be settled in Pfizer common stock on the fifth anniversary of the grant date. Settlement is contingent on satisfying vesting requirements, emphasizing long-term alignment between executive compensation and shareholder interests.

Are there vesting conditions on the Pfizer (PFE) stock appreciation rights grant?

Yes. The filing states that the stock appreciation rights are subject to certain vesting requirements. Only after these conditions are met will the rights be eligible to convert into shares of Pfizer common stock on the fifth anniversary of the grant date.

Does this Pfizer (PFE) Form 4 reflect a stock purchase or sale?

No open-market purchase or sale is reported. The Form 4 shows an acquisition coded as a grant or award of 259,844 stock appreciation rights, a derivative equity incentive that carries a zero purchase price and will later settle in Pfizer common shares.